XOMA (US) LLC (XOMA) Release: XOMA 052 Designated Orphan Drug by FDA for Treatment of Behcet's Disease  
8/4/2010 10:08:04 AM

BERKELEY, Calif., Aug. 4, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Food and Drug Administration has designated XOMA 052, an antibody to interleukin-1 beta, an orphan drug for the treatment of Behcet's disease. As previously announced, the Committee for Orphan Medical Products of the European Medicines Agency has recommended the granting of orphan medicinal product designation for XOMA 052 for the same indication in the European Union.